Oncoinvent ASA registers new share capital after private placement
Oncoinvent ASA has registered an increase in its share capital following a private placement and retail offering of new shares. The share capital increase has now been finalized.
Oslo, Norway – Oncoinvent ASA has registered its increased share capital following the issuance of 1,650,000 new shares. This capital increase is a result of a private placement and a retail offering that concluded in September 2026.
The private placement comprised two tranches, with the first tranche consisting of 990,689 shares and the second tranche including 540,311 shares. In parallel, a retail offering conducted via Nordnet allocated an additional 119,000 new shares to investors. The registration of these shares officially confirms the capital increase.
Oncoinvent ASA is a biotechnology company focused on developing novel cancer therapies. Its technology utilizes targeted alpha therapies, aiming to deliver highly potent radioactive isotopes directly to cancer cells. The funds raised are intended to support the company's ongoing research and development efforts, including clinical trials.
The company aims to advance new treatment options for patients with cancer. The successful completion of this share issuance provides Oncoinvent with financial resources to progress its pipeline and pursue its long-term strategic objectives in oncology.